

Biosimilars - PK studies in healthy subjects

Why Germany?

With a large number of inhabitants – more than 80 million- , a very high population density as well as large urban centers, Germany offers extremely good recruitment potential for studies with high sample sizes in healthy subjects.

A good social embedding of the people, the very good infrastructure and this in combination with a high quality standard ensures low drop-out rates and high data quality.

How does this work?

SocraTec R&D has successfully established a network of professional phase-I-CROs for this type of studies.

All participating phase I CROs enjoy an excellent reputation, combine decades of experience and all share a successful inspection history.

They are located in different densely populated areas of Germany and all have very good volunteer data bases.

SocraTec R&D as lead CRO sets up the trial, cares for quick and efficient regulatory and Ethic's approval, coordinates all sites in a competitive recruitment and takes over the the complete responsibility including sponsor's oversight. In an atmosphere of mutual trust, study coordination and recruitment are continuously optimized.


Optimum conditions for
bioequivalence studies with biosimilars!



Germany - excellent recruitment

Excellent recruitment numbers speak for themselves

With permission of the very satisfied client we are allowed to present the numbers of our recently finished initial project with a total of 491 subjects randomised within less than 5 months:



SocraTec R&D GmbH
Im Setzling 35
61440 Oberursel

Address

Telefon +49 (0)6171 58571-0
Fax +49 (0)6171 5857-25

info@socratec-pharma.de
www.socratec-pharma.de

Dr. Barbara Schug
André Warnke

Managing Directors

Bad Homburg v. d. Höhe
HRB 6590

Commercial Register